Research programs working toward an HIV cure. Covers reservoir reduction, prevention policy, tumor-like tissue models, and vaccine development.
The Aventis Pasteur statement emphasizes the continued development of its ALVAC vector as a preventive AIDS vaccine. The company remains committed to multiple trials using ALVAC-HIV (vCP1452) and supports research into its therapeutic potential, with ongoing phase I/II studies underway.
A new study using powerful DNA-amplification tests found that up to 3% of participants had untreated chlamydia and over 5% had untreated gonorrhea, suggesting a large reservoir of asymptomatic infections. The high prevalence rates in the general public and lack of symptoms emphasize the importance of screening programs and extended acc...
A study found that 35% of staff left the field within four years due to colleague stress. However, burnout was not a major factor; instead, support from professional colleagues significantly impacted employee retention. The researchers conclude that improving team relationships can reduce job stress and enhance retention.
The SMART trial aims to find a balance between aggressive HIV treatment and minimizing adverse side effects. The study will compare two distinct treatment approaches over an average of seven years, providing valuable insights into the optimal use of antiviral therapy.
A Mayo Clinic case study describes a patient with progressive multifocal leukoencephalopathy (PML) who responded positively to HAART-cidofovir combination therapy, regaining mobility and daily functioning. The case contributes to growing data on effective treatment strategies for PML in AIDS patients.
Two independent studies show that HIV infection increases T-cell death and proliferation, leading to a decline in CD4+ T cells. The accelerated division of existing T cells contributes to the immunodeficiency associated with HIV, rather than blocking new cell production.
A new study reveals that HIV-specific CD4+ T cells persist in infected individuals, but high virus levels suppress their proliferative response. The research provides clues on how the virus manipulates the immune system for its own survival and challenges the notion of long-term nonprogressors.
The North-Central California Center for AIDS Research aims to address HIV infection patterns, develop prevention strategies and improve treatment outcomes. The center will foster collaboration between researchers and clinicians to advance knowledge of HIV and its impact on rural communities.
Researchers at Gladstone Institute of Virology and Immunology found that HIV's Vpr gene causes the formation of nuclear herniations, disrupting cell division. This disruption enables virus production to increase severalfold, improving HIV's ability to grow and infect new cells.
The study aims to determine the effectiveness of meditation and/or massage in improving patients' perceived quality of life. Researchers hope to find ways to improve quality of life, particularly in the spiritual domain, for patients dying with AIDS.
Researchers found that infected individuals can transmit HIV to others through a single sexual encounter, often before developing flu-like symptoms. The study emphasizes the importance of not engaging in unsafe sex and highlights the need for early intervention to prevent rapid epidemic spread.
Researchers at Gladstone Institute discover HIV can infect naïve T cells, explaining how T-cell numbers diminish and leave the body susceptible to opportunistic infections. Infected naïve cells die, eliminating immune system's ability to respond to opportunistic infections characteristic of AIDS.
Peptide-T, a synthetic compound, prevents HIV from entering healthy human cells by adhering to specific cellular receptors. This new mechanism of action offers an alternative to existing protease inhibitors, which can develop resistance and cause harmful side effects.
Researchers have found a possible link between viral infections and a treatable form of ALS. Six patients with HIV developed symptoms of motor neuron disease after anti-HIV treatment, suggesting that the AIDS virus can cause a variant of classic ALS.
Researchers found that HIV-induced changes in B cells lead to dysfunctional antibody production and increased risk of cancer. The study provides a key tool to investigate how HIV causes B-cell malfunction and may lead to the development of new treatments for HIV-infected individuals.
A UCSF study of exclusive receptive oral intercourse with a male partner found a very low probability of acquiring HIV. The study involved 198 participants, none of whom contracted HIV through oral sex.
A recent study found that 85% of injection drug users in Baltimore obtained some needles from street sellers, highlighting the need for improved needle exchange programs. The study suggests that individually sealed syringes could be a game-changer in reducing the transmission of blood-borne diseases.
Researchers found that HAART decreased the HIV death rate to 38 percent of pre-HAART levels and opportunistic infections to 66 percent, supporting its effectiveness in advanced patients. The study analyzed data from 528 advanced AIDS patients who received HAART for an average of 15 months.
New Zealand scientists are presenting innovative research on meat storage, with freezing found to be the best way to preserve raw sheep meat. Researchers have also isolated a promising chemical from a native Asian tree for treating AIDS, cancer, and diabetes. Additionally, marine sponges have yielded compounds that may aid in fighting ...
Researchers have discovered a new family of anti-viral compounds, guanidinoglycosides, that target the genetic structure of HIV essential to its replication. These compounds aim to prevent HIV from forming and spreading throughout the body by targeting the 'Rev' protein responsible for producing and spreading infected cells.
The NIH has announced a new initiative and strategic plan for global AIDS research, with the goal of slowing the pandemic and reversing its destruction. The plan includes increased investment in global research, new funding approaches, and support for long-term research infrastructure.
Researchers discovered that STI-HAART can train the immune system to control HIV by developing a stronger response against the virus. The study provides a potential recipe for further research on restoring HIV-specific immunity after acute infection.
A large randomized trial evaluating a compound intended to boost the immune response of HIV patients showed no effect on slowing disease progression. The study, led by UCSF and Harvard researchers, defied the sponsor's attempt to block publication, affirming the University's right to publish unfavorable or neutral research findings.
Researchers argue that current HIV prevention resource allocations are not consistent with trends in the spread of HIV disease. They propose a shift in focus from AIDS case-based reporting to sentinel surveillance systems, citing data showing declining HIV prevalence and incidence among heterosexuals and stable rates among MSMs.
The Fogarty International Center has awarded a total of $15 million to support six new awards, three competing renewal awards, and 32 competing supplements for U.S. universities under the AITRP. The program focuses on building global HIV/AIDS research capacity and preventing HIV transmission in developing countries.
Leading AIDS researchers, including Robert Gallo and Seth Berkeley, urge a new era of scientific cooperation to accelerate HIV vaccine development. The epidemic affects 40 million people worldwide, and current funding and resources are insufficient.
Researchers analyzing blood samples from an anonymous test site in Santos, Brazil found a significant increase in HIV infection rates between 1995 and 1999. The majority of recent infections were among heterosexual women, who were also more likely to report anal sex and a history of sexually transmitted disease.
A new study finds that providing female condoms to commercial sex workers in rural South Africa is a highly cost-effective means of preventing HIV transmission. The analysis found that 5.9 cases of HIV, 38 cases of syphilis, and 33 cases of gonorrhea would be averted per year in 1,000 female condom recipients.
Researchers from UNC Chapel Hill present new approaches to HIV vaccine development, improved diagnostic training, and a method for identifying high-HIV transmission areas. They also reveal the role of Epstein-Barr virus in mouth disorders associated with AIDS.
The Special Issue of Science documents the devastating impact of AIDS in sub-Saharan Africa, with 24.5 million HIV-infected people facing inaccessible treatments and preventive tactics. The article highlights the need for increased funding, estimated to be between $1.6 billion and $2.6 billion annually.
AAAS and UCSF launch a premier online AIDS prevention information forum, linking peer-reviewed papers, daily features, and resources for scientists. The site aims to accelerate HIV vaccine development by facilitating global collaboration and information exchange.
Research reveals that individuals coping with HIV/AIDS exhibit diverse information-seeking behaviors, from avoiding information to seeking out multiple sources. Understanding these complexities is crucial in developing effective treatment programs, as uncertainty can be a natural part of life for some individuals.
The National Institute of Allergy and Infectious Diseases has launched a global network to develop and test preventive HIV vaccines. The network, known as the HIV Vaccine Trials Network (HVTN), will provide a comprehensive framework for conducting clinical trials globally.
A study of over 400 HIV-positive and negative heterosexual couples found that lower HIV blood levels are associated with reduced transmission risk. Individuals with viral loads below 1,500 copies/mL had no infected partners.
Researchers have found that CD8 cells can stop human immunodeficiency virus (HIV) in its tracks even when added to infected CD4 cells. This finding suggests a new approach to controlling the spread of HIV and could lead to potential therapeutic strategies.
Researchers at UCSF Center for AIDS Prevention Studies are conducting a quality-of-life study to understand challenges faced by HIV-positive individuals. The Unity Project aims to examine the effects of one-on-one interventions on managing healthcare, disclosing status, and dealing with sexuality.
A preliminary study found that 38% of HIV-positive people in low-income hotels took over 90% of their medication, adhering well to combination anti-viral therapy. The researchers also discovered a close relationship between medication adherence and viral suppression, with levels of HIV doubling for every 10% of missed pills.
The new facility will enable researchers to conduct major studies on HIV-1C, a subtype responsible for more than half of the world's infections. The lab aims to identify prevention and treatment strategies to combat the spread of this devastating virus in southern Africa.
Case Western Reserve University has received a five-year, $10 million grant from the NIH to continue AIDS research that began 13 years ago. The grant enables area residents to participate in studies offering free HIV testing and newly developed drugs for treatment.
The University of California, San Francisco is set to conduct a pioneering study on liver and kidney transplantation in HIV-infected patients. The research aims to determine the safety and efficacy of these procedures in individuals with end-stage liver and kidney disease, which are often fatal due to co-infection with hepatitis C virus.
The Adult AIDS Clinical Trials Group will receive $80 million in funding to continue studying antiviral interventions, immune system restoration, and opportunistic disease prevention. The network aims to improve patients' abilities to tolerate therapies and develop new strategies for treating HIV-related complications.
Dr. Bruce D. Walker delivers a lecture on immune-mediated control of HIV infection, highlighting the Wistar/Philadelphia FIGHT Collaborative Project. The project combines basic immunotherapy with community-based research involving over 4,000 individuals living with HIV/AIDS.
New research from UCSF reveals that HIV patients with high CD4+ counts are still at risk of opportunistic infections such as CMV retinitis. The studies found a relationship between the effectiveness of anti-CMV therapy and HAART, highlighting the need for careful consideration in treatment strategies.
A study by Rockefeller and Aaron Diamond researchers found that about one in six patients with the AIDS virus carried a strain resistant to at least one drug. The researchers recommend exploring the prevalence of this resistance and considering therapy structured around HIV-resistance testing to improve treatment effectiveness.
A new HIV drug intervention using nevirapine is significantly cheaper and more effective than three similar treatments, preventing 603 infections at a cost of $80,000 per year. The universal nevirapine program is the most cost-effective option, with a treatment cost of $138 to prevent one case of infant HIV.
A new study suggests that hope plays a vital role in maintaining the health of HIV-positive men who have lost a loved one to AIDS. The researchers found that optimistic expectations and feelings of control over the disease are associated with a slower rate of progression of HIV-related illness.
Researchers found that CMV infection accelerates the progression of HIV in infants, leading to motor problems, stunted brain growth, pneumonia, and other symptoms of AIDS. The study sheds light on how viruses interact to cause disease and may lead to further understanding of why some individuals have a faster progression of HIV.
Researchers found that HIV-infected pregnant women receiving care at specialized centers or state-funded sites were more likely to receive antiretroviral therapy, reducing transmission by up to two-thirds. The study highlights the importance of access to quality medical care in preventing mother-to-newborn transmission of AIDS.
Luis Montaner, a Wistar Institute scientist, has been awarded a $79,000 grant to support his HIV-1 Patient Partnership for Basic Research project. The project aims to find new treatments and develop vaccines for human immunodeficiency virus (HIV-1) through medical research.
Researchers sequenced the complete genome of a form of HIV from India, finding significant variation in genes for proteins on the outer envelope of the virus. This suggests that currently favored approaches to vaccine development may not work, and that a new approach may be needed.
Researchers found HIV's impact on T-cell production and its role in the immune system. The study involved measuring daily rates of new T-cell production in HIV-negative adults and those with suppressed virus, revealing a surprising increase in new cell production responsible for increased T-cell counts.
A recent trial found that patients with HIV-related sensory neuropathy experienced significantly lessened pain intensity and improved sensation after receiving injections of lab-created nerve growth factor. The study also identified which nerves are involved in the injury, paving the way for future research on regrowing damaged nerves.
The UCSF Center for AIDS Research has been awarded a major grant from the National Institutes of Health to support ongoing work in basic, clinical, and behavioral science areas of HIV/AIDS. The grant will focus on developing new treatment approaches, understanding HIV transmission, and improving therapy effectiveness.
The Emory/Atlanta CFAR is a multidisciplinary research center focusing on the prevention and treatment of HIV/AIDS. With a $2.3 million grant, it aims to foster collaboration among diverse HIV/AIDS programs in Atlanta.
Research participants advocate for full disclosure of experimental vaccine details, physical and social harm reduction, and community collaboration. They also want assurance of compensation, confidentiality, and support in case of adverse reactions.
A study found that 56% of HIV-infected gay men in the US are using combination therapy, but many are delaying treatment due to concerns about commitment and side effects. The study showed a strong link between advanced HIV infection and use of combination therapy.
A team of researchers documented a case of transmission of protease-resistant HIV, which is resistant to six of the 11 approved HIV anti-retroviral drugs. The patient was infected through unprotected anal intercourse with a partner who had previously been treated with these drugs, highlighting the need for continued prevention efforts.
A new study by University of California San Francisco researchers proposes expanding federal Medicaid coverage of HIV drugs to control the disease. The expansion would result in 9,600 more years of life for persons with HIV disease over five-years and prevent 4,200 deaths.
Researchers found that 11% of infected men were long-term nonprogressors at 10 years, but only 2% remained nonprogressors after 18 years. High plasma viral loads are a strong predictor of disease progression. Antiviral therapy is recommended for individuals with rising virus levels and high CD4 counts.
Researchers at Brown University found two independent cardiovascular disease risk factors in women taking HIV treatment cocktails: disfiguring extra fat around the torso and serum lipid levels. The study also documented another side effect: body fat changes, including prominent bellies and buffalo hump fat pads.